University Lab Technologies Files Patent for Cold & FLU RMD(TM)

University Lab Technologies announced today the filing of a patent with the United States patent office for its Evidence Based Nutraceutical Cold & FLU RMD(TM) product formulation for the treatment of the common cold.

BOCA RATON, Fla. (BusinessWire EON) May 5, 2007 -- Our announcement today represents University Lab Technologies' continuing mission to develop, patent, and bring to market nutraceutical product formulations using the principle's of Evidence Based Medicine (EBM). Further, this patent submission complements our current product line including the patent pending formulations Arthroleve(TM) and Zenstral PMS(TM). www.arthroleve.com www.zenstralpms.com

Dr. Jarret Morrow, President and Chief Scientific Officer of University Lab Technologies, was quoted saying, "We believe that our third patent application represents our continuing commitment of identifying, researching, and patenting formulations which are comprised of natural compounds that have clinically proven efficacy. While many of our competitors design products using folklore or simply copying other successful products, we strive to create innovation and to design products using EBM principles that are delivered in pharmaceutical grade preparations."

The OTC cold, flu, and allergy remedies market has recently been estimated around $2.8 billion in sales in the United States. In contrast, the cost to the economy reflected in lost productivity and medical cost, is estimated at over $30 billion. It is further estimated that North Americans themselves suffer from one billion cold, flu, and related symptoms each year. Currently the marketplace for nutraceutical Cold remedies is dominated by products containing either single ingredients such as Zinc, Vitamin C, or American Ginseng, or vast combination of holistic herbal preparations formulated at homeopathic or extremely diluted doses. In contrast, Cold & Flu RMD(TM) contains a patent pending formulation comprised of Andrographis Paniculata, Eleutherococcus senticosus, Panax quinquefolium, and Vitamin C that is delivered in a pharmaceutical grade preparation. Though there is no current cure for the common cold, University Lab Technologies' product contains ingredients which are clinically proven to reduce the severity of cold symptoms without any significant side effects. www.coldandflurmd.com

Dr. Morrow went on to say, "Recently, the public has become concerned regarding two separate safety issues involving our competitor's products including the potential side effects of Zinc. Further, potentially toxic levels of Vitamin A has recently been found in one the most popular selling cold products. We feel that these safety concerns represent a very significant opportunity for the launch of our patent-pending, revolutionary Cold & Flu RMD(TM) product."

About University Lab Technologies

Every year university labs around the globe identify, research and test natural compounds and formulations which have the potential to improve the quality of life of our lives.

Over 98% of these potentially life changing discoveries are never commercialized for the benefit of the public. University Lab Technologies, in collaboration with universities worldwide, researches and identifies those compounds that have proven evidence based effects and have the greatest potential for improving our lives.

University Lab Technologies' mission is to deliver the latest advances and discoveries in natural compounds packaged in our unique patented formulations and delivered to satisfy the needs of consumers for the treatment of many common chronic ailments. www.universitylabtechnologies.com

Optimized by Newsforce